Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,056.42 +38.03 (+0.76%) Dow
38,167.57 +264.28 (+0.70%) Nasdaq
15,800.20 +194.72 (+1.25%) Bitcoin USD
59,098.70 +1,975.84 (+3.46%) CMC Crypto 200
1,273.22 +2.48 (+0.20%)
Intellia Therapeutics, Inc. (NTLA)
| Previous close | 22.50 |
| Open | 22.80 |
| Bid | 23.18 x 100 |
| Ask | 23.25 x 200 |
| Day's range | 22.37 - 23.18 |
| 52-week range | 19.37 - 47.48 |
| Volume | |
| Avg. volume | 1,483,719 |
| Market cap | 2.236B |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.96 |
GlobeNewswireIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All par
- GlobeNewswire
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-upIntellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral pre
ZacksIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
